The US Food and Drug Administration (USFDA) is investigating two parts of the pharmaceutical company Dr. Reddy’s Laboratories while the US inspections were taken CNBC-TV18 learned on Wednesday.
Dr Reddy’s strategic plants where inspection began on October 18 are FT07 and FT09, located at Duvvada and Vishakapatnam.
FT07 is a sterile plant where oncology products such as injectibles, etc. are manufactured.
In 2015, FT07 was issued a notification after being reviewed by the USFDA in 2018. The US drug regulatory body issued 8 reviews of the affected area, in February 2019, The announcement was made to receive the Dr. Reddy’s Laboratories. A Certificate of Incorporation from the USFDA indicates that the contents are in good condition.
Watch the accompanying video of CNBC-TV18’s Ekta Batra for more details.
(Edited by : Kanishka Sarkar)
Originally Posted: IST